NCT00831974View on ClinicalTrials.gov

Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

February 28, 2007

Conditions
Mastocytosis
Interventions
DRUG

masitinib (AB1010)

3 mg/kg/day

DRUG

masitinib (AB1010)

6 mg/kg/day

Sponsors

Lead Sponsor

AB Science
All Listed Sponsors
lead

AB Science

INDUSTRY